Transient abnormal myelopoiesis/acute megakaryoblastic leukemia diagnosed in the placenta of a stillborn Down syndrome fetus with targeted next-generation sequencing

[1]  A. Tzankov,et al.  Morphologic and GATA1 sequencing analysis of hematopoiesis in fetuses with trisomy 21. , 2014, Human pathology.

[2]  A. Curley,et al.  GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. , 2013, Blood.

[3]  M. Bythell,et al.  Predictors of Survival in Children Born With Down Syndrome: A Registry-Based Study , 2012, Pediatrics.

[4]  P. Vyas,et al.  Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML , 2008, Leukemia.

[5]  D. Reinhardt,et al.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. , 2008, Blood.

[6]  P. Vyas,et al.  Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome , 2007, Nature Clinical Practice Oncology.

[7]  S. Scherer,et al.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. , 2003, Blood.

[8]  G. de Jong,et al.  Prenatal diagnosis of congenital leukemia in a fetus at 25 weeks' gestation with Down syndrome: case report and review of the literature , 2003, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[9]  A. Zipursky,et al.  Transient leukaemia – a benign form of leukaemia in newborn infants with trisomy 21 , 2003, British journal of haematology.

[10]  H. Hasle,et al.  Risks of leukaemia and solid tumours in individuals with Down's syndrome , 2000, The Lancet.

[11]  E. Niebuhr,et al.  Down's syndrome , 1974, Humangenetik.